BIOINFORMATICIAN FOR THE CANCER GENOMICS LAB

The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “Bioinformatician for the Cancer Genomics Lab”Reference: 2024-058-01 Application deadline: 30/11/2024Number of vacancies: 1Job description:We are seeking a bioinformatician to join the Cancer Genomics Lab at VHIO. The scope of the work will be mostly linked to the analysis of genomic data in the context of cancer patients. The successful applicant should be able to work in a team as well as independently and in several projects, be proactive and motivated. Requirements: Bioinformatician with knowledge/ experience in Genomics and Cancer (+2yrs).Familiar with raw sequencing data (FASTQ) as well as other common formats (SAM/BAM, BED, etc.), command-line tools (bwa, samtools, bedtools, etc.) and biological databases (cBioportal, COSMIC…).Fluency in R and/ or Python.Proficiency in English.Additional information: Knowledge of statistical modelling or machine learning will be considered a plus. Knowledge in database management systems (such as MySQL, mongoDB or noSQL).Experience in Docker and/ or Slurm.What we offer?The possibility of developing your professional career in a competitive environment.To be part of a centre that is constantly developing, pursuing excellence in research and collaborating with leading teams.We offer and promote a diverse and inclusive environment, and welcome all people equally, regardless of age, disability, gender, nationality, race, religion or sexual orientation.Working conditions:Full-time contract.Salary will be estimated according to profile and experience.Immediate incorporation.Flexible working hours and measures to reconcile work, family, personal life and gender equality, as stipulated in the VHIO agreement.Flexible remuneration programme (including restaurant vouchers, medical insurance, transport and childcare vouchers).23 days of holiday and 5 days of free disposal.Application: Candidates must submit a curriculum vitae and letter of intent via email: selecciorrhh@vhio.net, including the reference number “Ref. 2024-058-01” in the subject line of your email. The position is core funded. Salary conditions will be set according to experience and profile.About VHIO:The Cancer Genomics Lab provides cutting-edge applications in cancer genomics through state-of-the-art technologies and, importantly, the development of novel, fully validated tests. Our novel genomic tests provide an important added value to our activity, enabling routine patient testing in the clinical research setting (Prescreening Program) as well as in translational research. VHIO’s Prescreening Program is a transversal program, nucleated around the activity of two VHIO groups – the Molecular Oncology (led by Paolo Nuciforo) and Cancer Genomics labs, performing routine molecular profiling in over 1500 patients per year. Patients included in the program are candidates for enrollment in Phase I clinical trials carried out at the Research Unit for Molecular Therapy of Cancer (UITM) – “la Caixa”, led by Elena Garralda. Patients’ suitability for inclusion in any given clinical trial is decided taking into account their respective genomic or pathologic profile. The Cancer Genomics Lab has developed and implemented several tests during the last 10 years that have been in use in the Prescreening Program routine. Tests for DNA profiling in tissue are NGS-based: an Amplicon-seq hotspot panel to sequence 67 genes (developed back in 2012) and a custom 435-gene hybrid capture panel (VHIO-300, developed in 2018), and an nCounter (Nanostring) panel for RNA gene fusion detection (with the capacity of detecting over 100 recurrent gene fusions) and perform gene expression profiling. As a reflection of our dedication to excellence and quality in the services we provide, both NGS-DNA based tests have been accredited according to the UNE-EN ISO 15189 quality system, that specifies requirements for quality and competence in medical laboratories. In recognition to our track, VHIO-300’s UNE-EN ISO 15189 accreditation was awarded in its flexible version, allowing us to include new analytes directly in the accredited test (following a standard operating procedure).In 2021, we initiated the technical transfer of the Food and Drug Administration (FDA)-approved Guardant360® CDx liquid biopsy test for comprehensive genomic profiling. VHIO es the first cancer research center in Europe to have a laboratory equipped with this cutting-edge platform.Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.VHIO’s translation toward precision oncology: http://www.vhio.net